Biotech Values

[genisi]

Analysts at UBS think that Teva has already shipped a 3-4 months supply.

Here's ML take:
>Merrill Lynch's Gregg Gilbert explains, "At this time, we are not making any changes to our model (2007 earnings per share of $2.34, 2008 earnings per share of $2.56). We had earlier estimated that generic Protonix could contribute up to $184 million in sales and $0.11 per share earnings. Presently, neither Sun nor Wyeth (as an authorized generic) has launched, and our prior estimates could be conservative depending on the duration of Teva’s “sole” exclusivity." One reasons for Merrill holding back, and its "Neutral" rating on the shares, is a lack of financial clarity regarding the drug. "Management believes that Teva had a “relatively full” generic Protonix launch, but did not provide any quantitative color.<

And some cheerful local analysts:
http://globes-online.com/serveen/globes/DocView.asp?did=1000290372&fid=980